Enliven Therapeutics Announces Clinical Data in CML Patients with Atypical Fusion Transcripts at ASH 2025 Annual Meeting

ELVN-001 demonstrates encouraging anti-CML activity in heavily pretreated patients with atypical fusion transcripts Growing unmet need for patients with atypical transcript e13a3, which is resistant to TKIs targeting the myristoyl pocket BOULDER, Colo. ,  Nov.